Lv64
2630 积分 2024-04-03 加入
AML treatment: conventional chemotherapy and emerging novel agents
2天前
已完结
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
9天前
已完结
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
9天前
已完结
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
10天前
已完结
PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development
2个月前
已完结
High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer
2个月前
已完结
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma
2个月前
已完结
Exploring nondegrading molecular glues for protein–protein interactions
2个月前
已完结
Targeting Fibroblast Activation Protein for Precision Medicine
2个月前
已完结
Infigratinib Approved for Cholangiocarcinoma
2个月前
已关闭
皖公网安备34019202002308
